Adventris Pharmaceuticals
Adventris makes off-the-shelf cancer vaccines against KRAS, the most common cancer-driving gene, with the long-term idea of a yearly vaccine that prevents many cancers.
Overview
Adventris Pharmaceuticals, a Johns Hopkins spin-out, develops off-the-shelf therapeutic and preventive cancer vaccines using a platform designed to raise strong immune responses against poorly immunogenic oncogene-derived antigens. Its first vaccine targets mutant KRAS, relevant to pancreatic, colorectal and lung cancers, and the company's stated long-term vision is annual pan-cancer vaccination. Programmes are preclinical or early clinical; no sourced financing rounds are recorded here.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyGuardian Bio
Shares Off-the-shelf cancer vaccines, Y Combinator and the tag yc.
- CompanyTareBio
Shares Off-the-shelf cancer vaccines, Y Combinator and the tag yc.
- CompanyPersephone Biosciences
Shares Y Combinator, Colorectal cancer and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyREPROSENT
Shares Y Combinator and the tag yc.
- CompanyCofactor Genomics
Shares Y Combinator, Non-small-cell lung cancer and the tag yc.